<DOC>
	<DOCNO>NCT02718651</DOCNO>
	<brief_summary>Genetic rearrangement Anaplastic Lymphoma Kinase ( ALK ) gene result creation variety oncogenic fusion protein drive malignancy subset non-small cell lung cancer ( NSCLC ) patient . Treatment ALK small tyrosine kinase inhibitor ( TKI ) crizotinib produce remarkable result ALK-positive patient , however current diagnostic test use clinic sufficiently detailed require tumor biopsy . The aim study use new diagnostic test detect ALK rearrangements use next generation sequencing , improve diagnosis treatment ALK-positive NSCLC patient . Furthermore , test perform blood sample , make minimally invasive patient . It believe circulate tumor DNA ( ctDNA ) blood employ easy accessible comprehensive source information diagnose ALK-positive disease , also mean monitor patient response treatment . Quantitation amount ALK rearrangement give information patient benefit treatment treatment longer effective . The project multicenter study blood sample collect every 6 week patient treat four major hospital Denmark . This study benefit future patient lung cancer , improve monitor evaluation treatment . Monitoring patient treatment provide knowledge disease progression effect ALK-TKI treatment , contribute great selection patient , respond treatment . This potentially allow effective treatment continue longer conventional method</brief_summary>
	<brief_title>Blood-based Identification Monitoring Patients With ALK-translocated Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Nonsmall cell lung cancer diagnosis Biopsyverified ALKtranslocation Patients possible retrieve biopsy Patients squamous cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ALK rearrangement</keyword>
	<keyword>Circulating tumor DNA</keyword>
	<keyword>Plasma DNA</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
</DOC>